Survivorship Intervention Program in Western Kenya: Study Protocol

Launched by MOI UNIVERSITY · Nov 6, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on improving the care and support for children who have survived cancer in Western Kenya. The study aims to help caregivers—like parents—understand more about childhood cancer, its treatments, and any long-term effects that might occur after treatment. It will also provide training for healthcare providers to ensure they are well-equipped to follow up with these young survivors. By doing this, the researchers hope to encourage regular check-ups for children who have finished their cancer treatment and to better document any late effects they might face.

To take part in this study, caregivers of children under 15 years old who are finishing their cancer treatment will be eligible, along with healthcare providers working in the Pediatric Oncology department. Participants can expect to receive educational resources and support, and their feedback on the program’s effectiveness will be valued. This trial is not yet recruiting participants, but it aims to create a better understanding and care system for childhood cancer survivors and their families.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Caregivers of children diagnosed with cancer (primary or secondary malignancy) below fifteen years old.
• • Children will soon be finalizing childhood cancer treatment (enrolled during the last 2 months of treatment).
• • Healthcare providers (the pediatric oncology workforce comprises of an estimated 30 staff members) working in the Pediatric Oncology department at MTRH will be recruited.
• • Any cadre involved in patient care or patient education (e.g. pediatric oncologists, fellows, registrars, medical officers, clinical officers, nurses, patient navigators, child life specialists) will be allowed to participate.
• Exclusion criteria:
• • Childhood cancer patients should have no treatment failure (abandonment, relapsed disease, progressive disease).
• • Caregivers of children with a relapsed malignancy in remission will be excluded.